As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Tempest Therapeutics, Inc. The largest reported stake is Matthew Angel's, at 37.4%. 5 filings are on record since August 13, 2025 (Schedule 13D/A, March 25, 2026).
Sell to companies like Tempest Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Versant Venture Capital VI, L.P. · Sole voting: 16,149 · Shared voting: 0 · Sole dispositive: 16,149 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-04-02
- · Reporting person: Matthew Angel · Sole voting: 5,531,516 · Shared voting: 0 · Sole dispositive: 5,531,516 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-03-25
- · Holder: Matthew Angel · Percent: 35.9% · SCHEDULE 13D
- · Reporting person: Sabby Management, LLC · Sole voting: 0 · Shared voting: 492,223 · Sole dispositive: 0 · Shared dispositive: 492,223 · SCHEDULE 13G, 2026-01-21
- · Holder: Versant Venture Capital VI, L.P. · Percent: 3.7% · SCHEDULE 13D/A
Tempest Therapeutics, Inc. has 5 Schedule 13D or 13G filings on record since 2025-08-13. 2 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 37.4% | 5,531,516 | SCHEDULE 13D/A, 2026-03-25 | 2026-03-24 | |
| Sabby Management, LLC | 9.9% | 492,223 | SCHEDULE 13G, 2026-01-21 | 2025-12-31 |
| Versant Venture Capital VI, L.P. | 1.1% | 16,149 | SCHEDULE 13D/A, 2026-04-02 | 2026-03-30 |
Holding shares or following this stake? See who's behind Tempest Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Tempest Therapeutics, Inc. and the records around it.
Tempest Therapeutics, Inc. elsewhere on the record
- Company profile and every filing Oct 2026
- Form D filing Oct 2026
- Leadership changes Aug 2026
- Form D filing Jun 2026
- Who owns it
Companies that share a holder
- Versant Venture Capital VI, L.P. also filed stake reports on 3 other companies: Monte Rosa Therapeutics, Inc. (Jan 2026), LENZ Therapeutics, Inc. (Nov 2025), LAVA Therapeutics N.V. (Sep 2025)
- SABBY MANAGEMENT, LLC also filed stake reports on 15 other companies: Globavend Holdings Ltd (Jan 2026), Jiuzi Holdings, Inc. (Jan 2026), Big Tree Cloud Holdings Ltd (Jan 2026)
Watch Tempest Therapeutics, Inc.
Get an email when Tempest Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Tempest Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Tempest Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Tempest Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Matthew Angel | 5,531,516 | 0 | 5,531,516 | 0 | SCHEDULE 13D/A, 2026-03-25 |
| Sabby Management, LLC | 0 | 492,223 | 0 | 492,223 | SCHEDULE 13G, 2026-01-21 |
| Hal Mintz | 0 | 492,223 | 0 | 492,223 | SCHEDULE 13G, 2026-01-21 |
| Sabby Volatility Warrant Master Fund, Ltd. | 0 | 492,223 | 0 | 492,223 | SCHEDULE 13G, 2026-01-21 |
| Versant Venture Capital VI, L.P. | 16,149 | 0 | 16,149 | 0 | SCHEDULE 13D/A, 2026-04-02 |
| Versant Ventures VI GP, L.P. | 0 | 16,149 | 0 | 16,149 | SCHEDULE 13D/A, 2026-04-02 |
| Versant Ventures VI GP-GP, LLC | 0 | 16,149 | 0 | 16,149 | SCHEDULE 13D/A, 2026-04-02 |
| Versant Vantage II, L.P. | 162,972 | 0 | 162,972 | 0 | SCHEDULE 13D/A, 2026-04-02 |
| Versant Vantage II GP, L.P. | 0 | 162,972 | 0 | 162,972 | SCHEDULE 13D/A, 2026-04-02 |
| Versant Vantage II GP-GP, LLC | 0 | 162,972 | 0 | 162,972 | SCHEDULE 13D/A, 2026-04-02 |
| Versant Venture Capital IV, L.P. | 90,084 | 0 | 90,084 | 0 | SCHEDULE 13D/A, 2026-04-02 |
| Versant Side Fund IV, L.P. | 567 | 0 | 567 | 0 | SCHEDULE 13D/A, 2026-04-02 |
| Versant Ventures IV, LLC | 0 | 90,651 | 0 | 90,651 | SCHEDULE 13D/A, 2026-04-02 |
The latest filing identifies Tempest Therapeutics, Inc. by CUSIP 87978U108 and gives its principal executive office as 2000 Sierra Point Parkway, Suite 400, Brisbane, CA 94005 (SCHEDULE 13D/A, 2026-04-02).
Source of funds (Item 3)
On February 3, 2026, the Reporting Person acquired 4,837,070 shares pursuant to the Asset Purchase Agreement by and between the Issuer, Erigen LLC, a Delaware limited liability company ("Erigen"), and Factor Bioscience Inc., a Delaware corporation ("Factor" and together with Erigen, "Sellers") dated as of November 19, 2025 (the "Asset Purchase Agreement"), pursuant to which Sellers agreed to sell and transfer to the Issuer certain assets, in exchange for an aggregate purchase price of 8,268,495 shares of common stock of the Issuer, to be issued (the "Common Stock") to Erigen.Matthew Angel, SCHEDULE 13D/A, 2026-03-25
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-13 | Versant Venture Capital VI, L.P. | 3.7% | SCHEDULE 13D/A |
| 2026-01-21 | Sabby Management, LLC | 9.9% | SCHEDULE 13G |
| 2026-02-10 | Matthew Angel | 35.9% | SCHEDULE 13D |
| 2026-03-25 | Matthew Angel | 37.4% | SCHEDULE 13D/A |
| 2026-04-02 | Versant Venture Capital VI, L.P. | 1.1% | SCHEDULE 13D/A |
Questions about who owns Tempest Therapeutics, Inc.
Who owns Tempest Therapeutics, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Tempest Therapeutics, Inc.: Matthew Angel (37.4%, Schedule 13D/A, filed 2026-03-25) and Sabby Management, LLC (9.9%, Schedule 13G, filed 2026-01-21).
Who are the largest shareholders of Tempest Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Tempest Therapeutics, Inc. on this page are Matthew Angel (37.4%) and Sabby Management, LLC (9.9%).
When did Matthew Angel buy into Tempest Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Matthew Angel on this page is the Schedule 13D, filed 2026-02-10, reporting 35.9%; its latest, Schedule 13D/A filed 2026-03-25, reports 37.4%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Tempest Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 30, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| October 19, 2026 | Leadership change: John Frederick appointed, Director | — | Leadership changes | Source |
| October 14, 2026 | Form D, private offering | $7.50M sold | Form D page | Source |
| September 28, 2026 | Leadership change: Constance Ames appointed, Chief Financial Officer | — | Leadership changes | Source |
| August 24, 2026 | Leadership change: Nicholas Rossettos appointed, Chief Financial Officer | — | Leadership changes | Source |
| June 23, 2026 | Form D, private offering | $4.06M sold | Form D page | Source |
| June 4, 2026 | Leadership change: Justin Trojanowski appointed, Vice President, Finance | — | Leadership changes | Source |
| May 29, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| May 22, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| April 3, 2026 | Form D, private offering | $2M sold | Form D page | Source |
Tempest Therapeutics, Inc.: every filing and event
Tools for this story
Each opens in a new tab, filled in for Tempest Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.